Clinical Year in Review at #ACR23 By @philseo (@jhrheumatology) Review some of the most impactful scientific studies in #Rheumatology in the past year! 🍕 https://t.co/ystEjzrU8u

ARTIC REWIND RCT 3 yrs csDMARD withdrawal 38% 3yrs csDMARDs free remission vs. 80% stable dose gpe 75% recovery after restart Rx progression 19% in half dose gpe More use bioDMARDs (18%) & GCs (50%) withdraw gpe Trends towards lower infections @RheumNow #ACR23 #ACRBest https://t.co/jhOINV7LLS

Low dose #prednisone has (bad) brain effects. An argument to use steroid sparing drugs in #PMR ⁦@philseo⁩ ⁦@ACRheum⁩ ⁦@RheumNow⁩ #ACR23 THINK about steroid sparing Rx in ?all pts with #PMR #Great #debate https://t.co/usQJRNUN8B

#CAR T cells #ACR23 🔥Back to back Sessions on one of the most avidly researched area in Rheum! 💡Check out these slides to understand: ☣️Toxicities and Limitations of CAR T therapy 🆕 Novel CAR designs ⚡️CAR cell sources ❓Research Questions to ponder! #ACRambassador https://t.co/6sOn4rjqY3

Toxicities and limitations of CAR therapy: the other side of its incredibly exciting, boundless potential @Michel_Sadelain @MSKCancerCenter #ACR23 @RheumNow https://t.co/L1UIqqlOdC